Symptom-onset dosing with a serotonin reuptake inhibitor for PMDD may have a greater impact on anger/irritability and relationship functioning than other symptoms.
What Has a Greater Effect on Children’s Behavior: Prenatal Exposure to Antidepressants or Maternal Depression?
Maternal depression during the third trimester, not prenatal SSRI exposure, was associated with higher levels of internalizing and anxiety behaviors in children from 3 to 12 years of age.
A New Drug Application for zuranolone awaits FDA approval for the treatment of major depressive disorder (MDD) and postpartum depression (PPD).
Many women experience depression during pregnancy. What is the best way to identify these women?
Some studies have demonstrated associations between in utero exposure to antidepressants and cognitive outcomes.
SSRI and SNRI antidepressants were not associated with an increased risk for gestational diabetes.
The reality is that most of the antidepressants taken by women today are relatively safe and carry a very low risk to the developing fetus.
While we have data to support the use of antidepressants, including the selective serotonin reuptake inhibitors (SSRIs) and the serotonin norepinephrine reuptake inhibitors (SNRIs), during pregnancy, most studies have focused on risk of congenital [...]
This is the first installment of a new feature on our website: ESSENTIAL READS This is a kind of shortcut which allows you to find the most relevant reviews and articles in reproductive psychiatry. [...]
While we have heard a lot about brexanolone, marketed by Sage Therapeutics as Zulresso, for the treatment of postpartum depression, an oral version of this novel antidepressant – SAGE 217 or zuranolone – has been [...]